Unlocking the Economics of AAV Gene Therapy: Why DNA Input Choice Now Matters More Than Ever
AAV gene therapy is advancing rapidly—but its future may hinge on manufacturing economics, not science. As therapeutic doses climb and programs scale, cost of goods (COG) is emerging as a critical barrier, with plasmid DNA (pDNA) alone accounting for up to 40% of batch costs.
This article reveals how shifting to cell-free dbDNA™ fundamentally reshapes AAV manufacturing, delivering measurable gains in speed, purity, and efficiency. Economic modeling shows up to 22% COG reduction and millions in annual savings at commercial scale. For CSOs and CMC leaders, the implication is clear: DNA input is no longer a tactical choice—it’s strategic.
”Plasmid DNA alone can account for up to 40% of AAV batch costs — and switching to dbDNA™ can reduce overall COG by up to 22%.
Download the full article to explore detailed modeling, optimization scenarios, and the long-term impact on gene therapy scalability.
